Pre-clinical models using primary hepatocytes from human and rodent livers and rodent models, including high-fat-diet-induced obese mice and diabetic mouse models (e.g., db/db mice), have demonstrated dulaglutide’s efficacy in reducing hepatic steatosis and improving liver enzyme levels and insulin sensitivity [326,327,328]. Here, INS is linked to fatty liver disease.